Revance Therapeutics (NASDAQ:RVNC) is receiving new coverage from analysts at StockNews.com

StockNews.com initiated coverage of the stock of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research note issued to investors on Thursday. The brokerage has issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities analysts have recently issued reports on the stock. Mizuho decreased their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a neutral rating for the company in a research report on Friday, May 10th. HC Wainwright lowered shares of Revance Therapeutics from a strong-buy rating to a hold rating in a research report on Tuesday, August 13th. Stifel Nicolaus decreased their price target on Revance Therapeutics from $24.00 to $20.00 and set a buy rating on the stock in a research note on Friday, August 9th. Needham & Company LLC lowered shares of Revance Therapeutics from a moderate-buy rating to a hold rating in a research note on Tuesday, August 13th. Finally, Piper Sandler cut shares of Revance Therapeutics from a strong-buy rating to a hold rating in a report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Revance Therapeutics has an average rating of Hold and an average price target of $10.88.

Check out the latest stock report on RVNC

Revance Therapeutics stock fell 0.2%

RVNC opened at $6.59 on Thursday. The stock has a market cap of $690.76 million, a price-to-earnings ratio of -1.82 and a beta of 0.98. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $19.01. The company has a 50-day moving average of $3.79 and a 200-day moving average of $4.20.

Revance Therapeutics (NASDAQ:RVNC – Get Your Free Report ) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million for the quarter, compared to analyst estimates of $66.30 million. During the same period in the previous year, the business posted EPS of ($0.80). The company’s quarterly revenue was up 20.2% compared to the same quarter last year. As a group, analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional investors are taking note of Revance Therapeutics

A number of hedge funds have recently made changes to their positions in RVNC. Certuity LLC purchased a new position in Revance Therapeutics in the second quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Revance Therapeutics during the second quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new position in Revance Therapeutics in the second quarter valued at about $38,000. Nisa Investment Advisors LLC boosted its stake in Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 18,077 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Revance Therapeutics by 52.5% in the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 7,628 shares during the period. 97.70% of shares are currently owned by institutional investors.

About Revance Therapeutics

(Get a free report)

Revance Therapeutics, Inc, a biotechnology company, is engaged in the development, manufacture and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed Phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Read more

Get news and reviews for Revance Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revance Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.